Epigenomics, Predictive Biosciences Extend Agreement on Prostate Cancer Dx | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Epigenomics and Predictive Biosciences today said that Predictive Biosciences will develop a prostate cancer test using the GSTP1 biomarker, under a licensing agreement extension.

The agreement, originally forged in 2009, gave Predictive the option to develop the test using the biomarker. In announcing today that it is executing that option, Predictive added that it will also commercialize the test. In return, Epigenomics will receive a one-time fee.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: researchers identify the characteristic genomic features of clear cell renal cell carcinoma, and more.

A technology that has the potential to make species go extinct could be used against the Zika virus. 

University of the Republic postdoc Victor Morais says researchers should be careful of the open access journals they choose to publish in.

If science funding agencies can talk tough about sexual harassers, shouldn't they also put their talk into action?

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.